Supplementary Table1

5% CCS medium

	siRNA	**CT**		**E_2**		**HRGβ1**	
		24h	48h	24h	48h	24h	48h
G1	CT	61±2	78±1	59±1	60±2	60±3	66±1
	Cks1	72±2	63±3	66±1	54±2	67±2	49±2
S	CT	22±1	12±1	26±2	30+3	25±2	24±2
	Cks1	8±1	8±1	11±1	12±1	10±1	7±1
G2/M	CT	17±1	10±1	15±1	10±1	14±2	10±2
	Cks1	20±2	30±2	22±2	34±3	23±2	44±2

5% FBS medium

	siRNA	**CT**		**ICI**		**ICI + E_2**		**ICI + HRG β1**	
		24h	48h	24h	48h	24h	48h	24h	48h
G1	CT	55±1	61±2	61±2	75±3	56±1	62±1	57±1	66±1
	Cks1	74±3	53±1	76±2	57±1	74±2	56±3	73±2	50±1
S	CT	32±2	32±2	23±1	15±1	30±2	30±2	27±2	24±2
	Cks1	11±1	11±1	7±1	5±1	10±2	8±1	7±1	6±2
G2/M	CT	10±1	8±1	17±2	10±2	14±1	9±2	16±2	10±1
	Cks1	15±1	36±2	18±1	38±1	16±2	36±2	20±2	44±3

Data represent proportion of cells in each cell cycle phase as percent of total population and are means ± SEM of triplicates. MCF-7/LacZ cells were transfected with either a control siRNA or a Cks1-specific siRNA for 24h, followed by indicated treatments in CCS or FBS medium for another 24 or 48h. Cells were then harvested, and DNA stained with propidium iodide, followed by flow cytometric analysis.